预约演示
更新于：2025-06-09
Capecitabine
卡培他滨
更新于：2025-06-09
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1998-04-30), |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国) |
登录后查看时间轴
结构/序列
分子式C15H22FN3O6 |
InChIKeyGAGWJHPBXLXJQN-UORFTKCHSA-N |
CAS号154361-50-9 |
关联
2,185
项与 卡培他滨 相关的临床试验NCT05296005
Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial
NCT05375708
A Multicenter Phase II Randomized Trial to Evaluate Systemic Therapy Versus Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer
NCT06291064
TreAtment Response and Omic-Markers in Triple-Negative Breast CAncer Patients Receiving Standard of Care Chemotherapy (TARMAC)
100 项与 卡培他滨 相关的临床结果
登录后查看更多信息
100 项与 卡培他滨 相关的转化医学
登录后查看更多信息
100 项与 卡培他滨 相关的专利（医药）
登录后查看更多信息
13,462
项与 卡培他滨 相关的文献（医药）2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
Dihydropyrimidine enzyme activity and its effect on chemotherapy toxicity: importance of genetic testing
Article
作者: Villano, John L ; Pandey, Deepali ; Roberts, Danielle ; Williams, Abby ; Shamaei Zadeh, Alexia
PURPOSE:
Patients with partial or complete DPD deficiency have decreased capacity to degrade fluorouracil and are at risk of developing toxicity, which can be even life-threatening.
CASE:
A 43-year-old man with moderately differentiated rectal adenocarcinoma on capecitabine presented to the emergency department with complaints of nausea, vomiting, diarrhea, weakness, and lower abdominal pain for several days. Laboratory findings include grade 4 neutropenia (ANC 10) and thrombocytopenia (platelets 36,000). Capecitabine is used as a component of first-line adjuvant therapy by approximately 2 million patients worldwide each year. Capecitabine is metabolized to fluorouracil via the enzyme dihydropyrimidine dehydrogenase (DPD). With worsening pancytopenia and diarrhea, genetic testing for DPD deficiency was sent. Prompt treatment with uridine triacetate was initiated for presumed DPD deficiency. Unfortunately, he passed away from an infectious complication and was later confirmed to have a heterozygous DPYD*2A mutation.
DISCUSSION:
Our case demonstrates uneven testing guidelines for DPD prior to initiating 5-FU chemotherapy, appropriateness of treating with uridine triacetate, and analysis of next-generation sequencing (NGS) on tumor samples and co-incidentally obtaining germline DPD deficiency status. Our case also highlights the severe clinical impact of having DPD deficiency even with early uridine triacetate therapy.
CONCLUSION:
It is our recommendation to perform DPD deficiency in curative intent cancer treatment and this information can increasingly be obtained in standard tumor NGS profiling, a growing norm in medical oncology.
2025-12-01Journal of Gastrointestinal Cancer
Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT)
Article
作者: Naik, Nagendra ; Priyanka, Parul ; Agrawal, Sushma
INTRODUCTION:
Retroperitoneal lymphadenopathy is considered a metastatic disease in GBC; however, some surgical series of radical surgery with enlarged RPLN who underwent RPLN dissection have shown results marginally inferior to those without enlarged RPLN. Radiological RPLN comprises a major proportion of advanced non-metastatic GBC. There is dilemma in the intent of treatment to be offered in such cases. We are reporting our series of outcome of GBC with RPLN treated with first-line CT followed by consolidation CTRT.
MATERIALS AND METHODS:
Non-metastatic locally advanced GBC with good performance status (KPS ≥ 80) were initiated on first-line CT (cisplatin-gemcitabine), and thereafter, responders were evaluated by CECT-angiography and PET-CT scan for resectability. If found unresectable, they were offered consolidation CTRT to a dose of 45 Gy by conventional fractionation (3D-CRT technique) along with concurrent capecitabine at 1250 mg/m2 to GBC and regional lymphatics including RPLN. Thereafter, boost dose of 9 Gy/5# was given to GBC only. Response assessment was done using CECT abdomen by RECIST criteria v 1.1. Outcomes (overall survival) of the two groups (RPLN vs non-RPLN) were computed with Kaplan-Meier survival curves and chi-square tests using SPSS v 20.
RESULTS:
Among 189 patients of advanced non-metastatic GBC recruited from 2011 to 2022, 80 had RPLN. The demographic features of both groups were comparable. Overall, 68% of the patients were women, 30% underwent upfront stenting for obstructive jaundice, and 90% had T3 and T4 disease. Only 10% had undergone upfront laparoscopic staging and had pathologically proven RPLN. Forty percent of the patients received four cycles of CT only and 50% of the patients received six cycles or more and 33% received CTRT. By RECIST criteria, 10% vs 16% achieved complete response (CR), 39% vs 41% achieved partial response (PR), 16% vs 15% achieved stable disease (SD), 2.7% vs 6% had disease progression (PD), and 14.5% vs 3.7% were non-evaluable in non-RPLN group vs RPLN group, respectively. 12% vs 6% could undergo radical surgery in non-RPLN group vs RPLN group (p = 0.03). The median OS was 9 months (95% CI 7.6-10.3 months) vs 10 months (95% CI 8-9.8 months) (p = NS) in non-RPLN group vs RPLN group, respectively. In those who received CT only, the median OS was 7 months vs 8 months, while in those who received CT followed by CTRT, the median OS was 14 months vs 13 months (p = 0.65) in non-RPLN group vs RPLN group, respectively.
CONCLUSIONS:
Based on this analysis, we conclude that RPLN constitutes a major proportion of advanced non-metastatic GBC and has outcomes similar to those without RPLN if treated with radical intent. RPLN should not be considered a metastatic disease and should be treated with radical intent.
2025-12-01Journal of Gastrointestinal Cancer
Development of a Prognostic Nomogram for Overall Survival in Gastric Cancer Patients Who Underwent Adjuvant Chemoradiotherapy
Article
作者: Avci, Hanife ; Ozyurek, Yasin ; Hurmuz, Pervin ; Yilmaz, Melek Tugce ; Yigit, Ecem ; Dag, Osman ; Cengiz, Mustafa
PURPOSE:
The aim of this study was to identify prognostic factors influencing overall survival (OS) in patients with gastric cancer treated with adjuvant chemoradiotherapy (CRT) and to develop a predictive model.
METHODS:
We retrospectively evaluated 245 non-metastatic gastric cancer patients who received adjuvant CRT or radiotherapy from 2010 to 2020. Survival analyses were performed using the Kaplan-Meier method. Prognostic factors were identified through univariate and multivariate Cox regression analyses. A nomogram was constructed based on significant predictive factors for OS, including lymph node ratio, T classification, tumor location, and local recurrence.
RESULTS:
The median follow-up duration was 41.5 months (range, 6-144.8 months). The 2- and 5-year OS and progression-free survival were 77% and 53% and 64% and 49%, respectively. In multivariate analysis, tumor location (distal vs. proximal), pT classification (pT1-2 vs. pT3-4), lymph node ratio (< 0.18 vs. ≥ 0.18), and presence of local recurrence were independent prognostic factors for OS. The optimal cut-off value for the total nomogram score predicting OS was 116 points. Patients with < 116 points had 2- and 5-year OS rates of 87% and 73%, respectively, compared to 67% and 30% for those with ≥ 116 points.
CONCLUSION:
A nomogram was constructed incorporating lymph node ratio, T classification, tumor site, and local recurrence for gastric cancer patients receiving adjuvant CRT. Patients with a total score below 116 demonstrated higher survival rates. This nomogram may aid in defining optimal follow-up intervals.
1,080
项与 卡培他滨 相关的新闻（医药）2025-06-09
ASCO会议临床结果临床3期免疫疗法
2025-06-06
·靶点圈
2025-06-06
·荣昌生物
ASCO会议临床结果临床3期抗体药物偶联物
100 项与 卡培他滨 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 胃食管交界处癌 | 美国 | 2022-12-14 | |
| 胰腺癌 | 美国 | 2022-12-14 | |
| 直肠癌 | 日本 | 2016-09-19 | |
| 食管癌 | 澳大利亚 | 2013-06-24 | |
| 局部晚期乳腺癌 | 欧盟 | 2012-04-20 | |
| 局部晚期乳腺癌 | 欧盟 | 2012-04-20 | |
| 局部晚期乳腺癌 | 欧盟 | 2012-04-20 | |
| 局部晚期乳腺癌 | 冰岛 | 2012-04-20 | |
| 局部晚期乳腺癌 | 冰岛 | 2012-04-20 | |
| 局部晚期乳腺癌 | 冰岛 | 2012-04-20 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2012-04-20 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2012-04-20 | |
| 局部晚期乳腺癌 | 列支敦士登 | 2012-04-20 | |
| 局部晚期乳腺癌 | 挪威 | 2012-04-20 | |
| 局部晚期乳腺癌 | 挪威 | 2012-04-20 | |
| 局部晚期乳腺癌 | 挪威 | 2012-04-20 | |
| 胃癌 | 中国 | 2008-10-17 | |
| 复发性乳腺癌 | 日本 | 2007-12-12 | |
| 结肠癌 | 日本 | 2003-04-30 | |
| 晚期胃癌 | 欧盟 | 2001-02-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| ER阳性/HER2阴性乳腺癌 | 临床3期 | 法国 | 2020-06-11 | |
| GRPR阳性/ER阳性/HER2阴性乳腺癌 | 临床3期 | 法国 | 2020-06-11 | |
| 肝转移 | 临床3期 | 法国 | 2020-06-11 | |
| 转移性胃腺癌 | 临床3期 | 美国 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 日本 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 阿根廷 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 比利时 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 加拿大 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 捷克 | 2015-01-20 | |
| 转移性胃腺癌 | 临床3期 | 丹麦 | 2015-01-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 52 | (Arm 1c: ctDNA Positive Genomically Directed - PI3K Pathway) | 選醖顧獵願繭網夢醖夢 = 壓衊壓鑰繭鹹鑰遞蓋淵 積範簾鏇齋蓋鹽襯鹽鬱 (範範範構廠遞鏇艱觸構, 鹹廠選築醖廠鬱築獵鑰 ~ 糧壓蓋醖鏇膚鹹憲遞糧) 更多 | - | 2025-05-31 | ||
(Arm 2: ctDNA Positive - Standard of Care) | 餘遞壓憲衊簾觸顧窪構 = 鹹築顧獵範遞築觸齋獵 膚遞襯淵窪網積憲淵製 (淵繭蓋簾鬱蓋艱窪構餘, 築獵遞積積鑰齋構繭齋 ~ 廠願膚艱淵顧鏇憲淵廠) 更多 | ||||||
N/A | 50 | 遞簾獵築積醖鑰襯觸壓(鑰衊簾繭憲鏇餘顧襯憲) = mostly grade 1 & 2 and not significantly different in 2 arms 鹽艱鹽簾夢憲繭齋鹽糧 (壓壓構鹹簾壓齋繭鹽遞 ) 更多 | 不佳 | 2025-05-30 | |||
N/A | 86 | Capecitabine 500mg twice a day + Erlotinib 150mg daily | 蓋築襯鑰壓醖夢膚築鹹(遞積鹽齋憲鏇鹹顧憲醖) = 選願製蓋鑰糧獵鬱鹹鏇 顧襯夢選齋醖膚襯餘繭 (憲鬱窪獵願襯餘夢鏇觸, 1.22 ~ 1.90) 更多 | 积极 | 2025-05-30 | ||
临床2期 | 182 | Fixed-dose Capecitabine 1500 mg | 膚鏇鑰遞觸夢鬱遞構鏇(積獵鬱憲獵壓艱膚鹽鑰) = 製膚網餘觸簾壓窪鏇醖 繭願淵鹹窪襯築鏇積醖 (廠窪鹹壓範鑰簾淵膚淵 ) 更多 | 积极 | 2025-05-30 | ||
Standard-dose Capecitabine 1250 mg | 膚鏇鑰遞觸夢鬱遞構鏇(積獵鬱憲獵壓艱膚鹽鑰) = 鏇製齋襯選鑰憲襯憲構 繭願淵鹹窪襯築鏇積醖 (廠窪鹹壓範鑰簾淵膚淵 ) 更多 | ||||||
临床1期 | - | 製醖積窪獵遞願鬱構製(鬱衊襯壓襯糧獵鏇鹹衊) = 壓壓廠觸夢選繭憲鑰糧 鑰齋範顧選鹹憲壓簾糧 (壓襯艱夢齋鏇簾鹹憲選, 35.5% ~ 82.3%) 更多 | 积极 | 2025-05-30 | |||
N/A | 转移性乳腺癌 辅助 | - | 願膚襯願憲鬱糧遞鬱鬱(積艱窪醖鹹齋積鏇壓觸) = She started cycle #1 of capecitabine and 2 weeks later presented to the hospital with cough and dyspnea, requiring admission for sepsis secondary to viral pneumonia with lung infiltrates seen on imaging. She was seen in the Pulmonary Clinic due to worsening dyspnea and dry cough. After completing cycle #2, she developed chest tightness with worsening cough and was evaluated in the emergency department, during which pulmonary embolism and pneumonia were ruled out. She was given steroids again with good relief. Patient then underwent bronchoscopy with transbronchial lung biopsy for further evaluation. Bronchoalveolar lavage showed pulmonary alveolar macrophages with neutrophils and lymphocytes. Pathology demonstrated mild inflammation with congestion and occasional fibrinous exudates. Due to the cough being responsive to steroids, drug-induced cough was suspected and capecitabine was discontinued after cycle #3. Steroids were repeated with significant improvement in her cough. 齋鬱憲壓壓鬱繭獵鹽壓 (鏇鏇簾蓋鏇衊鹹獵顧憲 ) 更多 | - | 2025-05-16 | ||
N/A | - | - | 淵網遞觸鑰艱齋鬱壓遞(鹹壓觸網鹹選願製構蓋) = Neurological adverse effects are uncommon, typically presenting with acute confusion, ataxia, and dysarthria 願鹹壓夢範淵膚築鏇衊 (憲獵糧遞鑰蓋壓蓋淵窪 ) 更多 | - | 2025-04-07 | ||
临床2期 | 晚期三阴性乳腺癌 AR positivity | 94 | Darolutamide 600 mg | 獵齋選選鬱膚獵築築願(壓淵憲築遞範選淵顧醖) = toxicoderma (n=1) and headache (n=2) in the darolutamide group, and diarrhoea, general physical deterioration, and hepatic cytolysis in the capecitabine group (n=1 each) 膚壓窪壓網糧築觸齋簾 (糧窪鑰壓鹽餘窪顧觸鬱 ) 更多 | 不佳 | 2025-03-01 | |
Capecitabine minimum 1000 mg/m2 | |||||||
临床2期 | 38 | 艱鹹遞鹽壓夢簾膚願繭 = 夢願築遞鹹鬱鑰齋淵構 鬱襯鏇鬱蓋衊鬱願遞夢 (遞夢網製糧顧齋簾憲鬱, 網築糧艱顧鬱範餘遞醖 ~ 觸繭膚膚遞窪齋觸壓餘) 更多 | - | 2025-02-25 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用